Compare BOW & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOW | ARVN |
|---|---|---|
| Founded | 2020 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 913.3M | 806.0M |
| IPO Year | 2024 | 2018 |
| Metric | BOW | ARVN |
|---|---|---|
| Price | $28.70 | $12.11 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 23 |
| Target Price | ★ $36.00 | $17.89 |
| AVG Volume (30 Days) | 195.9K | ★ 1.1M |
| Earning Date | 11-04-2025 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.10 | N/A |
| EPS | ★ 1.53 | N/A |
| Revenue | ★ $519,241,000.00 | $312,300,000.00 |
| Revenue This Year | $16.05 | $11.06 |
| Revenue Next Year | $25.43 | N/A |
| P/E Ratio | $18.76 | ★ N/A |
| Revenue Growth | 33.44 | ★ 93.86 |
| 52 Week Low | $23.50 | $5.90 |
| 52 Week High | $42.29 | $21.00 |
| Indicator | BOW | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 59.62 | 53.36 |
| Support Level | $27.97 | $11.20 |
| Resistance Level | $28.95 | $12.50 |
| Average True Range (ATR) | 0.86 | 0.53 |
| MACD | 0.15 | -0.14 |
| Stochastic Oscillator | 85.88 | 41.10 |
Bowhead Specialty Holdings Inc offers commercial specialty property and casualty insurance products. The company offers underwriting solutions to various businesses across four underwriting divisions, which include Casualty, Professional Liability, Healthcare Liability, and Baleen Specialty. A majority of its revenue is generated from the Casualty division which specializes in general liability coverage, which protects a company against liability arising from bodily injury, personal injury or property damage, for risks in the construction, distribution, heavy manufacturing, real estate, public entity and hospitality segments and also considers underwriting risks in a broader range of industries. Geographically, the company operates in the United States.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.